11:26 uur 31-08-2016

ERYTECH houdt conference call over tweede kwartaal op 7 september

LYON, Frankrijk–(BUSINESS WIRE)– ERYTECH (Euronext Paris: FR0011471135 – ERYP) (Paris:ERYP) (ADR:EYRYY), de Franse biofarmaceutische ontwikkelaar van innovatieve behandelingen van acute leukemie en andere kankersoorten door middel van ‘uithongering’ van tumoren, heeft vandaag bekendgemaakt dat het op dinsdag 6 september 2016 zijn tweedekwartaalcijfers en bedrijfsupdate presenteert. Het gaat om het kwartaal dat eindigde op 30 juni 2016.

De directie van ERYTECH houdt op woensdag 7 september 2016 om 15.00 CET (09.00 am EDT) een conference call en webcast, waarin ze de belangrijkste financiële en operationele punten in het tweede kwartaal en eerste halfjaar van 2016 bespreekt. Ceo en bestuursvoorzitter Gil Beyen, financieel en operationeel bestuurder Eric Soyer en hoofd marketing Iman El-Hariry geven een korte presentatie, gevolgd door vraag- en antwoordsessie.

 

 

ERYTECH to Hold Q2 2016 Business Update Conference Call on September 7th, 2016

 

LYON, France–(BUSINESS WIRE)– ERYTECH (Euronext Paris: FR0011471135 – ERYP) (Paris:ERYP) (ADR:EYRYY), a French biopharmaceutical company developing innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, today announced that it will release its financial results and business update for the quarter ended June 30, 2016 on Tuesday, September 06, 2016 after the close of trading on the Euronext Paris.

ERYTECH management will hold a conference call and webcast on Wednesday, September 07, 2016 at 15:00pm CET / 9:00am EDT to review the Q2 and 1H 2016 financial and operational highlights. Gil Beyen, Chairman and CEO, Eric Soyer, CFO and CFO and Iman El-Hariry, CMO will deliver a brief presentation, followed by a Q&A session.

Investors and analysts wishing to participate can access the call via the following teleconferencing numbers:

USA: +1 8778874163 United-Kingdom: +44 2030432440
Switzerland: +41 225809022 Germany: +49 69222229031
France: +33 172001510 Belgium: +32 24029640
Sweden: +46 850334664 Finland: +358 942599700
Netherlands: + 31 107138194

Confirmation Code: 79702432#

The webcast can be followed live online via the link:
http://www.anywhereconference.com?UserAudioMode=DATA&Name=&Conference=135303493&PIN=79702432

Following the live call, a replay will be available for 90 days. To listen to the replay, please dial:

USA: +1 877 64 230 18
United-Kingdom: +44(0) 2033679460
France: +33(0)1 72 00 15 00

Confirmation Code: 303493#

Additionally, an archive of the webcast will be available on the “Webcast” section of the Company’s investor relations site at www.erytech.com

About ERYTECH and eryaspase (eryasp/GRASPA®): www.erytech.com

Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH’s initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), by depriving tumors of nutrients necessary for their survival. ERYTECH has recently filed for European Marketing Authorization for its lead product candidate, eryaspase, also known as eryasp or under the trade name GRASPA®, following positive efficacy and safety results from its completed Phase 2/3 pivotal clinical trial in Europe in children and adults with relapsed or refractory ALL. ERYTECH also has an ongoing Phase 1 clinical trial of eryaspase in the United States in adults with newly diagnosed ALL, and a Phase 2b clinical trial in Europe in elderly patients with newly diagnosed AML, each in combination with chemotherapy.

Eryaspase (GRASPA) consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells, from circulating blood plasma.

Every year over 50,000 patients in Europe and the United States are diagnosed with ALL or AML. For about 80% of these patients, mainly adults and relapsing patients, current forms of L-asparaginase cannot be used due to their toxicity or as a result of allergic reactions. ERYTECH believes that the safety and efficacy profile of eryasp/GRASPA®, as observed in its Phase 2/3 pivotal clinical trial, offers an attractive alternative option for the treatment of leukemia patients.

ERYTECH believes that ERY-ASP has the potential as a treatment approach in solid tumors and is conducting a Phase 2 clinical trial in Europe in patients with metastatic pancreatic cancer. In addition to its current product candidates that focus on using encapsulated enzymes to induce tumor starvation, ERYTECH is exploring the use of its platform for developing cancer vaccines and enzyme replacement therapies.

The EMA and the U.S. Food and Drug Administration (FDA) have granted orphan drug designations for eryaspase (GRASPA) for the treatment of ALL, AML and pancreatic cancer. ERYTECH produces the product at its own GMP-approved and operational manufacturing site in Lyon (France), and at a site for clinical production in Philadelphia (USA). ERYTECH has entered into licensing and distribution partnership agreements for ALL and AML in Europe with Orphan Europe (Recordati Group), and for ALL in Israel with TEVA, which will market the product under the GRASPA® brand name.

ERYTECH is listed on Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP) and is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes. ERYTECH is also listed in the U.S. under an ADR level 1 program (OTC, ticker EYRYY).

Forward-looking information

This document may contain forward-looking statements and estimates with respect to the financial position, results of operations, business strategy, plans, objectives and anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond the ERYTECH’s control. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Documents filed by ERYTECH Pharma with the French Autorité des Marchés Financiers ( www.amf-france.org), also available on ERYTECH’s website ( www.erytech.com) describe such risks and uncertainties. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this document. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the ERYTECH’s expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law.

Contacts

ERYTECH
Gil Beyen
Chairman and CEO
or
Eric Soyer
CFO and COO
+33 4 78 74 44 38
investors@erytech.com
< span>or
The Ruth Group
Lee Roth, +1 646 536 7012
lroth@theruthgroup.com
Investor relations
or
Kirsten Thomas, +1 508 280 6592
Media relations
kthomas@theruthgroup.com
or
< b>NewCap
Julien Perez
Investor relations
or
Nicolas Merigeau
Media relations
+33 1 44 71 98 52
erytech@newcap.eu

Check out our twitter: @NewsNovumpr